Annual report pursuant to Section 13 and 15(d)

Segments (Details)

v3.7.0.1
Segments (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Segment Reporting Information [Line Items]                      
Lymphoseek sales revenue $ 2,332,000 $ 6,690,000 $ 4,232,000 $ 3,783,000 $ 2,953,000 $ 3,503,000 $ 1,964,000 $ 1,835,000 $ 17,037,098 $ 10,254,352 $ 4,233,953
Lymphoseek license revenue 0 1,296,000 246,000 254,000 550,000 250,000 250,000 83,000 1,795,625 1,133,333 300,000
Grant and other revenue 1,023,000 511,000 917,000 686,000 477,000 541,000 654,000 190,000 3,136,983 1,861,622 1,740,896
Total revenue                 21,969,706 13,249,307 6,274,849
Cost of goods sold, excluding depreciation and amortization                 2,192,902 1,654,800  
Research and development expenses, excluding depreciation and amortization                 8,882,576 12,777,116  
Selling, general and administrative expenses, excluding depreciation and amortization                 12,616,334 16,796,490  
Depreciation and amortization                 501,369 571,419  
Income (loss) from operations (2,433,000) $ 3,358,000 $ (580,000) $ (2,568,000) (4,323,000) $ (2,601,000) $ (3,811,000) $ (7,816,000) (2,223,475) (18,550,518) (27,632,956)
Other income (expense), excluding equity in the loss of R-NAV, LLC                 (12,070,397) (9,902,424)  
Equity in the loss of R-NAV, LLC                 (15,159) (305,253) (523,809)
Benefit from income taxes                 0 436,051 0
Net loss from continuing operations                   (28,322,144)  
Income from discontinued operations, net of tax effect                 0 758,609 0
Net income (loss)                 (14,309,031) (27,563,535) (35,726,669)
Total assets, net of depreciation and amortization 12,461,676       14,964,513       12,461,676 14,964,513  
Payments to Acquire Property, Plant, and Equipment                 1,847 39,001 $ 1,114,448
U S                      
Segment Reporting Information [Line Items]                      
Lymphoseek sales revenue                 16,982,234 10,229,659  
Total assets, net of depreciation and amortization 12,329,143       14,552,834       12,329,143 14,552,834  
Non Us [Member]                      
Segment Reporting Information [Line Items]                      
Lymphoseek sales revenue                 54,864 24,693  
Total assets, net of depreciation and amortization 132,533       411,679       132,533 411,679  
Diagnostics Segment [Member]                      
Segment Reporting Information [Line Items]                      
Lymphoseek license revenue                 1,795,625 1,133,333  
Grant and other revenue                 3,012,217 1,861,622  
Total revenue                 21,844,940 13,249,307  
Cost of goods sold, excluding depreciation and amortization                 2,192,902 1,654,800  
Research and development expenses, excluding depreciation and amortization                 8,120,425 12,046,221  
Selling, general and administrative expenses, excluding depreciation and amortization                 3,652,154 5,852,214  
Depreciation and amortization                 104,138 281,314  
Income (loss) from operations                 7,775,321 (6,585,242)  
Other income (expense), excluding equity in the loss of R-NAV, LLC                 0 0  
Equity in the loss of R-NAV, LLC                 0 0  
Benefit from income taxes                   0  
Net loss from continuing operations                   (6,585,242)  
Income from discontinued operations, net of tax effect                   0  
Net income (loss)                 7,775,321 (6,585,242)  
Payments to Acquire Property, Plant, and Equipment                 0 26,589  
Diagnostics Segment [Member] | U S                      
Segment Reporting Information [Line Items]                      
Lymphoseek sales revenue                 16,982,234 10,229,659  
Total assets, net of depreciation and amortization 3,610,354       3,948,971       3,610,354 3,948,971  
Diagnostics Segment [Member] | Non Us [Member]                      
Segment Reporting Information [Line Items]                      
Lymphoseek sales revenue                 54,864 24,693  
Total assets, net of depreciation and amortization 131,752       410,666       131,752 410,666  
Therapeutics Segment [Member]                      
Segment Reporting Information [Line Items]                      
Lymphoseek license revenue                 0 0  
Grant and other revenue                 124,766 0  
Total revenue                 124,766 0  
Cost of goods sold, excluding depreciation and amortization                 0 0  
Research and development expenses, excluding depreciation and amortization                 762,151 730,895  
Selling, general and administrative expenses, excluding depreciation and amortization                 63,158 123,884  
Depreciation and amortization                 0 0  
Income (loss) from operations                 (700,543) (854,779)  
Other income (expense), excluding equity in the loss of R-NAV, LLC                 0 0  
Equity in the loss of R-NAV, LLC                 0 0  
Benefit from income taxes                   0  
Net loss from continuing operations                   (854,779)  
Income from discontinued operations, net of tax effect                   0  
Net income (loss)                 (700,543) (854,779)  
Payments to Acquire Property, Plant, and Equipment                 0 0  
Therapeutics Segment [Member] | U S                      
Segment Reporting Information [Line Items]                      
Lymphoseek sales revenue                 0 0  
Total assets, net of depreciation and amortization 15,075       0       15,075 0  
Therapeutics Segment [Member] | Non Us [Member]                      
Segment Reporting Information [Line Items]                      
Lymphoseek sales revenue                 0 0  
Total assets, net of depreciation and amortization 0       0       0 0  
Corporate Non Segment [Member]                      
Segment Reporting Information [Line Items]                      
Lymphoseek license revenue                 0 0  
Grant and other revenue                 0 0  
Total revenue                 0 0  
Cost of goods sold, excluding depreciation and amortization                 0 0  
Research and development expenses, excluding depreciation and amortization                 0 0  
Selling, general and administrative expenses, excluding depreciation and amortization                 8,901,022 10,820,392  
Depreciation and amortization                 397,231 290,105  
Income (loss) from operations                 (9,298,253) (11,110,497)  
Other income (expense), excluding equity in the loss of R-NAV, LLC                 (12,070,397) (9,902,424)  
Equity in the loss of R-NAV, LLC                 (15,159) (305,253)  
Benefit from income taxes                   436,051  
Net loss from continuing operations                   (20,882,123)  
Income from discontinued operations, net of tax effect                   758,609  
Net income (loss)                 (21,383,809) (20,123,514)  
Payments to Acquire Property, Plant, and Equipment                 1,847 12,412  
Corporate Non Segment [Member] | U S                      
Segment Reporting Information [Line Items]                      
Lymphoseek sales revenue                 0 0  
Total assets, net of depreciation and amortization 8,703,714       10,603,863       8,703,714 10,603,863  
Corporate Non Segment [Member] | Non Us [Member]                      
Segment Reporting Information [Line Items]                      
Lymphoseek sales revenue                 0 0  
Total assets, net of depreciation and amortization $ 781       $ 1,013       $ 781 $ 1,013